Search Results
Feb 19, 2026, 19:29 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory
More news about: Pomerantz LLP
Feb 19, 2026, 19:29 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Beyond Meat, Inc. and Certain Officers - BYND
foregoing was likely to impair Beyond Meat's ability to timely file its periodic filings with the U.S. Securities and Exchange Commission ("SEC"); and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.The complaint alleges that
More news about: Pomerantz LLP
Feb 19, 2026, 19:29 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Plug Power Inc. and Certain Officers - PLUG
facilities necessary to receive those funds; (ii) as such, Plug Power was likely to pivot toward more modest projects with less commercial upside; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.On October 7, 2025, Plug Power issued
More news about: Pomerantz LLP
Feb 19, 2026, 19:29 ET Pomerantz Law Firm Announces the Filing of a Class Action Against CoreWeave, Inc. and Certain Officers - CRWV
that CoreWeave's reliance on a single third-party data center supplier presented for CoreWeave's ability to meet customer demand for its services; (iii) the foregoing was reasonably likely to have a material negative impact on the Company's revenue; (iv) as a result, the Company's public statements were
More news about: Pomerantz LLP
Feb 19, 2026, 19:21 ET FIBRA Prologis anuncia que Terrafina obtuvo autorización de la CNBV para la cancelación de la inscripción de sus CBFIs en el Registro Nacional de Valores
condiciones económicas nacionales, internacionales, regionales y locales, (ii) cambios en los mercados financieros, tasas de interés y tipos de cambio, (iii) mayor competencia (prevista o no) por nuestras propiedades, (iv) riesgos asociados con adquisiciones, disposiciones y desarrollo de propiedades, (v)
More news about: FIBRA Prologis
Feb 19, 2026, 19:14 ET FIBRA Prologis anuncia que Terrafina obtuvo autorización de la CNBV para la cancelación de la inscripción de sus CBFIs en el Registro Nacional de Valores
condiciones económicas nacionales, internacionales, regionales y locales, (ii) cambios en los mercados financieros, tasas de interés y tipos de cambio, (iii) mayor competencia (prevista o no) por nuestras propiedades, (iv) riesgos asociados con adquisiciones, disposiciones y desarrollo de propiedades, (v)
More news about: FIBRA Prologis
Feb 19, 2026, 18:24 ET FIBRA Prologis Announces that Terrafina Obtained CNBV Authorization for the Cancellation of the Registration of its CBFIs in the National Securities Registry
(i) national, international, regional and local economic conditions; (ii) changes in financial markets, interest rates and foreign exchange rates; (iii) increased (anticipated or unanticipated) competition for our properties; (iv) risks associated with property acquisitions, dispositions and development;
More news about: FIBRA Prologis
Feb 19, 2026, 18:02 ET i-80 Gold Reports Fourth Quarter and Full Year 2025 Results; Continues to Advance Development Plan
resulting in (i) higher waste development rates required to catch up on development, (ii) additional capital required for dewatering infrastructure, (iii) lower grades processed in 2026 due to the delay in accessing the higher grade South Pacific Zone. Additionally, relative to the PEA, both recoveries
More news about: i-80 Gold Corp
Feb 19, 2026, 17:31 ET Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
arthritis and atopic dermatitis, emerging clinical evidence supports its possible use in alopecia areata. The therapy is presently undergoing Phase III clinical evaluation for this indication.Legacy Healthcare's Coacillium, a botanical therapy developed by Legacy Healthcare, has shown encouraging
More news about: DelveInsight Business Research, LLP
Feb 19, 2026, 16:46 ET FNF Reports Fourth Quarter and Full Year 2025 Financial Results
market risk benefit;iii. Purchase price amortization: the impacts related
More news about: Fidelity National Financial, Inc.
Feb 19, 2026, 16:38 ET The Chemours Company Reports Fourth Quarter and Full Year 2025 Results
Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes
More news about: The Chemours Company
Feb 19, 2026, 16:30 ET Select Medical Holdings Corporation Announces Results For Its Fourth Quarter and Year Ended December 31, 2025, Its 2026 Business Outlook, and Cash Dividend
(1)Refer to table III for calculation of earnings per common share.N/M
More news about: Select Medical Holdings Corporation
Feb 19, 2026, 16:15 ET F&G Annuities & Life Reports Fourth Quarter and Full Year 2025 Results
the life of the market risk benefit;(iii) Purchase price amortization: the impacts related to the amortization of certain intangibles (internally developed software, trademarks and value of
More news about: F&G Annuities & Life, Inc.
Feb 19, 2026, 16:15 ET RE/MAX HOLDINGS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
organic revenue growth as revenue growth from continuing operations excluding (i) revenue from Marketing Funds, (ii) revenue from acquisitions, and (iii) the impact of foreign currency movements. The Company defines revenue from acquisitions as the revenue generated from the date of an acquisition to
More news about: RE/MAX Holdings, Inc.
Feb 19, 2026, 16:08 ET AMH Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
properties and other, net for consolidated properties and unconsolidated real estate joint ventures, (ii) acquisition and other transaction costs and (iii) hurricane-related charges, net. The actual amounts for any and all of these items could significantly impact our 2026 GAAP net income and, as disclosed
More news about: AMH
Feb 19, 2026, 16:02 ET GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
cancers, and four-fold higher cancer detection rate when compared to standard of care alone. While there was a trend towards reduction in combined Stage III and IV, the trial did not meet the primary endpoint of a statistically significant reduction.Completed analysis of the full
More news about: GRAIL, Inc.
Feb 19, 2026, 16:01 ET Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate
at Stages I through III, including reduction in Stage IV cancer diagnoses.Key trial results include:The primary endpoint of statistically significant Stage III-IV reduction was not observed. However, there was a favorable trend toward fewer Stage III-IV cancers in a pre-specified
More news about: GRAIL, Inc.
Feb 19, 2026, 13:31 ET Notice convening the Annual General Meeting 2026 of Essity Aktiebolag (publ)
for 2028, as follows: (i) for the President, a maximum of 50 percent, (ii) for other members of the senior management, a maximum of 80 percent and (iii) for other Participants, a maximum of 50 percent. The maximum variable remuneration level shall be determined per individual, taking into account the
More news about: Essity
Feb 19, 2026, 13:28 ET Notice convening the Annual General Meeting 2026 of Essity Aktiebolag (publ)
for 2028, as follows: (i) for the President, a maximum of 50 percent, (ii) for other members of the senior management, a maximum of 80 percent and (iii) for other Participants, a maximum of 50 percent. The maximum variable remuneration level shall be determined per individual, taking into account the
More news about: Essity
Feb 19, 2026, 13:25 ET Une première mondiale en soins néonatals : le Japon approuve les fortifiants 100 % à base de lait humain de Prolacta Bioscience en tant que médicament sur ordonnance pour les nourissons vulnérables
l'examen de l'Agence japonaise des produits pharmaceutiques et des dispositifs médicaux (PMDA) de classe mondiale. L'essai multicentrique de phase III, randomisé, contrôlé, ouvert et dirigé par le Japon a évalué la croissance et la sécurité associées aux fortifiants à 100 % à base de lait humain de
More news about: Prolacta Bioscience
Feb 19, 2026, 13:23 ET Eine Weltneuheit in der Neugeborenenpflege: Japan genehmigt die zu 100 % aus Muttermilch hergestellten Nahrungsergänzungsmittel von Prolacta Bioscience als verschreibungspflichtiges Medikament für gefährdete Säuglinge.
japanische Arzneimittel- und Medizinprodukteagentur (PMDA) ein. Die von Japan geleitete randomisierte, kontrollierte, offene, multizentrische Phase-III-Studie untersuchte das Wachstum und die Sicherheit im Zusammenhang mit den zu 100 % aus Muttermilch hergestellten Nahrungsergänzungsmitteln von Prolacta
More news about: Prolacta Bioscience
Feb 19, 2026, 12:36 ET Rosalind Franklin University Innovation and Research Park Welcomes Clinical Research Organization's Phase I/II Clinical Site
multimedia:https://www.prnewswire.com/news-releases/rosalind-franklin-university-innovation-and-research-park-welcomes-clinical-research-organizations-phase-iii-clinical-site-302692908.htmlSOURCE
More news about: Rosalind Franklin University of Medicine and Science
Feb 19, 2026, 12:20 ET INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - RARE
Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate ("AFR"), such that the second interim analysis could be performed and presented to the investing public; and (ii) in truth, Ultragenyx' optimism in the Phase III Orbit study's results
More news about: Robbins Geller Rudman & Dowd LLP
Feb 19, 2026, 10:00 ET Soundcore Capital Partners Closes Oversubscribed Fund III at $450 Million
New York–based private equity firm, is pleased to announce the successful final close of Soundcore Capital Partners Fund III LP (together with its affiliated entities, "Fund III" or "the Fund") with $450 million of capital commitments and total demand in excess of its self-imposed hard cap.
More news about: Soundcore Capital Partners
Feb 19, 2026, 09:45 ET Pentagon Pours $68M Into Hypersonic Tech: Here Are Five Firms Building the Hardware
focused on advancing solid fuel ramjet propulsion technology. The ATLAS program receives funding from the U.S. Department of Defense under Title III of the Defense Production Act."The Starfighters team provided a reliable, flight-ready supersonic platform that enabled us to conduct
More news about: USA News Group